ERBB2 and breast cancer: According to published data [33], we assumed that the distribution of patient demographic and clinical characteristics in women with 21-gene recurrence scores in SEER were similar to the distributions observed in the overall population of women diagnosed with node positive (nodes 1–3), hormone response positive, HER2 negative breast cancer.